Publication of Prospectus Regulatory Announcement Royal

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
Publication of Prospectus

Regulatory Announcement Royal Bank of Canada January 21, 2016 Publication of Prospectus Not for release, publication or distribution, directly or indirectly, in or into the United States. Royal Bank of Canada has agreed to issue CNY 195,000,000 5.15 per cent. Notes due 25 January 2019, Series 25219 (the "Notes") pursuant to its Programme for the Issuance of Securities (the "Programme"). The following document constitutes the final terms dated January 21, 2016 (the "Final Terms") relating to the admission to trading of the Notes for purpose of Article 5.4 of Directive 2003/71/EC and must be read in conjunction with the Prospectus dated October 30, 2015, as supplemented by the 1st Supplementary Notes Base Prospectus dated December 14, 2015 relating to the Programme (the "Prospectus").  Full information on Royal Bank of Canada and the offer of the Notes is only available on the basis of the combination of the Final Terms and the Prospectus. DISCLAIMER - INTENDED ADDRESSEES Please note that the information contained in the Prospectus and the Final Terms, may be addressed to and/or targeted at persons who are residents of particular countries (specified in the Prospectus) only and is not intended for use and should not be relied upon by any person outside these countries and/or to whom the offer contained in the Final Terms is not addressed.  Prior to relying on the information contained in the Final Terms you must ascertain from the Prospectus, as supplemented by these Final Terms, whether or not you are part of the intended addressees of the information contained therein. The Notes have not been and will not be registered under the United States Securities Act of 1933, as amended (the "Securities Act") and are subject to US tax law requirements.  Subject to certain exceptions, the Securities may not be offered, sold or delivered in or into the United States or to or for the account or benefit of US persons (as defined in Regulation S under the Securities Act). No public offering of the Securities is being made in the United States. Your right to access this service is conditional upon complying with the above requirement. To view the full document, please paste the following URLs into the address bar of your browser. http://www.rns-pdf.londonstockexchange.com/rn...6-1-21.pdf For further information, please contact Paul Guthrie Assistant General Counsel Royal Bank of Canada Telephone Number:  (416) 974-6516 Fax Number:  (416) 955-2032 Email:  paul.guthrie@rbc.com This information is provided by RNS The company news service from the London Stock Exchange END

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Top 5 Most Recently Viewed Articles

Investigation of Stock Transactions: TASK, VBTX, TURN Insights

Updated Category News Views 125

Financial Investigations for Shareholders of TASK, VBTX, and TURN Halper Sadeh LLC is actively investigating several companies regarding potential violations of federal securities laws affecting shareholders. The investigations focus on significant transactions involving TaskUs, Veritex Holdings, and 180 Degree Capital Corp. TaskUs, Inc. and Its Acquisition by Blackstone...

Continue Reading
Comprehensive Analysis of NVIDIA in the Semiconductor Market

Updated Category News Views 678

Understanding NVIDIA's Position in the Semiconductor Sector In today's fast-paced business environment, it is crucial for investors and industry followers to conduct in-depth analyses of key companies. This article offers a detailed comparison of NVIDIA (NASDAQ: NVDA) with its main competitors in the Semiconductors & Semiconductor Equipment sector. By looking at important...

Continue Reading
Invivyd Set to Showcase PEMGARDA™ Findings at Upcoming Event

Updated Category News Views 54

Invivyd Prepares for IDWeek 2024 Presentations Invivyd, Inc. (NASDAQ: IVVD) is an innovative biopharmaceutical company focusing on creating solutions for serious viral infections. As they gear up for their participation in IDWeek 2024, they will be unveiling exciting new data concerning their investigational monoclonal antibody, PEMGARDA™ (pemivibart). The conference is...

Continue Reading
The Rising Stars: Growth Potential of Key Investments

Updated Category News Views 95

Carnival made waves post-pandemic as it clawed its way back from meme stock purgatory. Traders watched the cruise line stumble but now see flickers of recovery amidst hefty debt burdens that peaked around $35 billion. Sure, they pulled in a whopping $1.7 billion net income in the last quarter, but those profit forecasts? All over the place—talk about a mixed bag. And...

Continue Reading
PharmAla Partners with Logistics Expert for Clinical Trials

Updated Category News Views 114

PharmAla Forms Strategic Alliance for Enhanced US Distribution PharmAla Biotech Holdings Inc. (“PharmAla” or the “Company”) (CSE: MDMA) (OTC:MDXXF), a dedicated biotechnology company, is excited to share its latest strategic move aimed at improving service delivery in the United States. The company has engaged a trusted third-party logistics partner, specialized...

Continue Reading